Celldex Therapeutics Stock
Celldex Therapeutics Stock
There is an upward development for Celldex Therapeutics compared to yesterday, with an increase of €0.44 (1.440%).
Currently there is a rather positive sentiment for Celldex Therapeutics with 15 Buy predictions and 3 Sell predictions.
As a result the target price of 38 € shows a positive potential of 22.94% compared to the current price of 30.91 € for Celldex Therapeutics.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Celldex Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | 1.440% | 0.066% | 3.218% | 57.062% | 38.500% | -7.104% | -13.878% |
| Larimar Therapeutics Inc. | -2.370% | 2.976% | 9.494% | 7.453% | 4.217% | 13.816% | -58.563% |
| Northwest Biotherapeutics Inc. | 0.000% | 3.333% | -6.627% | -23.267% | -24.757% | -68.238% | -84.500% |
| Achieve Life Sciences Inc. | -1.830% | 0.926% | 10.772% | 141.150% | 47.297% | 7.921% | -14.844% |
Comments
Celldex Therapeutics (CLDX) had its price target lowered by Wells Fargo & Company from $54.00 to $48.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Morgan Stanley from $44.00 to $40.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Cantor Fitzgerald from $67.00 to $61.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
News
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics (NASDAQ:CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of
